GE HealthCare announced the launch of the Voluson Signature 20 and 18 ultrasound systems, which comprehensively integrate artificial intelligence (AI), adv...
QIAGEN has announced the approval of its NeuMoDx human immunodeficiency virus type 1 (HIV-1) assay for use in Thailand. This approval completes the suite o...
Observation: ACROBiosystems' relentless commitment to innovation and strategic partnerships underscores its pivotal role in advancing organoid research and...
Incyte and China Medical System Holdings Limited are pleased to announce that on March 31, 2024, Incyte and CMS, through a wholly-owned dermatology m...
GE HealthCare (Nasdaq: GEHC) announces the U.S. FDA 510(k) Clearance of IONIC Health’s revolutionary nCommand Lite technology, aimed at mitig...
Isansys Lifecare, led by the visionary Keith Errey, has gained recognition in the global healthcare technology market, particularly through its suc...
QIAGEN has announced a collaborative effort with the International Panel Physicians Association (IPPA) to bolster awareness of tuberculosis (TB) screening ...
Financial results of fiscal 2023 Net sales decrease organically by 1.6% to € 21.0 billion EBITDA pre down organically by 9.0% to € ...
The Change Healthcare Ransomware Payment Change Healthcare, a key player in the medical services sector owned by UnitedHealth Group, fell victim t...
MHTC has made significant strides in advancing agency-wide operational excellence which has been crucial to strengthening its foundation and positioning th...
Expands Viatris' Portfolio of Innovative Assets by Immediately Adding Two Phase 3 Assets, Selato...
- Biktarvy Now First and Only INSTI-Based Single-Tablet Regimen That is FDA Approved and DHHS Guideline Recommended for People Who are Virologically ...
Bitterroot Bio, a leader in innovative treatments for cardiovascular diseases, and Biotheus, a pioneer in monoclonal and multi-specific antibody design, an...
Approval based primarily on results from Phase 3 trial showing Dupixent significantly reduced itch compared to placebo CSU is the fifth approved...
© 2025 Biopharma Boardroom. All Rights Reserved.
